Psilocybin-Research.comSearchable psilocybin and psilocin bibliometric database.
Alerts
Email alerts
App & offline
Offline R analysis

Data sources

Source-labeled psilocybin and psilocin literature for search, monitoring, export, and citation workflows.

How the research index is built

Eight research sources feed Psilocybin-Research.com PubMed, OpenAlex, Crossref, Europe PMC, ClinicalTrials.gov, PsyArXiv, bioRxiv, and medRxiv provide records that are reconciled into the central research index. psilocybin-research.com PubMed OpenAlex Crossref Europe PMC ClinicalTrials.gov PsyArXiv bioRxiv medRxiv
Source records are fetched, reconciled, and labeled before appearing in the live index. The original sources remain authoritative.

Research workflow

Search, filter, export, analyze, and monitor publications with source labels, publication status, citation links, alerts, API access, and a rights-safe SQLite download. Read about the methods and limitations. Explore the dataset and reuse guide or research trends by year.

Published

Safety and Efficacy of Psilocybin During Anticancer Treatment: A Phase II Trial Secondary Analysis

An abstract is available from the original source but is not redistributed by this database. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal
Journal of Pain and Symptom Management
Date
2026-11-01
Source
Crossref
DOI
10.1016/j.jpainsymman.2026.07.030
PubMed
42546985

Authors

Schaefer Daniel A.Agrawal ManishMazzola EmanueleLeff Michelle K.Leeks CeliaKematick Benjamin S.Beaussant Yvan
Watch author

Derived topics and classifications

These labels are search aids derived from indexed metadata, not an assessment of evidence quality. Verify the study design and findings in the original source.

psilocybin Clinical TrialSafety Clinical Trial

Citation graph

10 referenced DOIs found in stored source metadata. 0 indexed papers cite this DOI.

Open citation network

10.1186/s12888-025-06599-510.3390/jcm1206219610.1080/0284186070146054110.1200/jco.2011.40.892210.1177/026988111667551210.1177/026988111667551310.1002/cncr.3501010.1002/cncr.3588910.3389/fphar.2024.139168910.1056/nejmoa011871

Related papers

PSilocybin Microdose for psYCHological and Existential Distress in PALliative Care (PSYCHED-PAL): A Multi-site Phase 3 Double-blind, Placebo-controlled, Parallel-arm Clinical TrialClinicalTrials.gov · 2026-07-10PSilocybin for psYCHological and Existential Distress in PALliative Care (PSYCHED-PAL): A Multi-site, Open-label, Single Arm Phase I/II Proof-of-concept, Dose-finding, and Feasibility Clinical TrialClinicalTrials.gov · 2026-07-10Group format psychedelic-assisted therapy interventions: Observations and impressions from the HOPE trialJournal of Psychedelic Studies · 2023-01-18Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) therapy for patients with advanced cancer: protocol for a multi-method feasibility trial.Pilot and feasibility studies · 2025-10-28Effect of MDMA-assisted therapy on mood and anxiety symptoms in advanced-stage cancer (EMMAC): study protocol for a double-blind, randomised controlled trial.Trials · 2024-05-21Psilocybin-Assisted Therapy in the Management of Anxiety and Depression Among Cancer PatientsDigital Showcase Research, Scholarship, & Creative Works (University of Lynchburg) · 2026-05-22The Safety and Efficacy of Psilocybin Therapy Compared to Low-dose Control in Reducing Depressive Symptoms in Patients With COPD, ALS, MS, or APD.ClinicalTrials.gov · 2026-05-08PSILOCYBIN AS AN ADJUNCTIVE TREATMENT FOR DEPRESSION AND PSYCHOLOGICAL DISTRESS IN ONCOLOGY: CURRENT EVIDENCE AND CLINICAL IMPLICATIONSInternational Journal of Innovative Technologies in Social Science · 2026-03-19